Introduction {#sec1}
============

As one of the immune checkpoint inhibitors, PD-1 and its ligands PD-L1 and PD-L2 mediate a signaling pathway critical for maintenance of peripheral tolerance.[@bib1] PD-1 is highly expressed on the surface of activated immune cells, including T cells, B cells, natural killer T cells, macrophages, and dendritic cells. PD-L1 is also expressed on activated immune cells such as T cells, B cells, macrophages, and dendritic cells. In addition, the expression of PD-L1 on the surface of many tissue cells, including those of the heart, lung, thymus, spleen, and kidney, is upregulated after interferon γ (INF-γ) stimulation. In contrast, the expression of PD-L2 is restricted to dendritic cells, macrophages, mast cells, and a subset of B cells.[@bib1], [@bib2] The PD-1/PD-L1 pathway inhibits T cell antigen receptor signaling (thereby blocking cytokine production), inhibits T cell proliferation and differentiation, and promotes apoptosis of effector T cells as well as development of regulatory T (Treg) cells.[@bib3], [@bib4]

The PD-1/PD-L1 pathway plays a dominant role in tumor immune evasion. PD-L1 is overexpressed in a variety of cancer types and tumor-associated antigen-presenting cells.[@bib5], [@bib6], [@bib7], [@bib8] Overexpression of PD-L1 in the tumor microenvironment and peripheral blood is associated with a poor prognosis for cancer patients.[@bib5], [@bib9], [@bib10], [@bib11] When PD-1 on activated T cells interacts with PD-L1 on tumor cells, tumor cells are protected from cytotoxic lysis, whereas T cells are functionally impaired and lapse into anergy, exhaustion, or apoptosis.[@bib12], [@bib13], [@bib14], [@bib15] Monoclonal antibodies (mAbs) targeting PD-L1 or PD-1 have been approved for clinical treatment of several cancer types, particularly advanced solid tumors.[@bib15], [@bib16], [@bib17]

However, therapeutic mAbs have their limits for clinical application because of the requirement of frequent administration and high cost. In this study, we tried to address these issues by taking an active immunization approach. We designed a vaccine targeting PD-L1 and assessed its immunogenicity and anti-tumor efficacy in mice. Our data showed that the PD-L1 vaccine reversed the suppressive functions of the PD-1/PD-L1 pathway in the tumor microenvironment and provided tumor control in both preventive and therapeutic mouse melanoma models. Therefore, the PD-L1 vaccine is promising as an alternative strategy for anti-PD-L1 mAb-based cancer therapy.

Results {#sec2}
=======

The Design and Purification of the DPDL1E Antigen {#sec2.1}
-------------------------------------------------

The tertiary structure of PD-L1 is composed of an extracellular domain (ECD), a transmembrane domain, and an intracellular region.[@bib18], [@bib19] Because the ECD is responsible for binding of PD-1, we have chosen this domain as an immunogen. Because of central tolerance, the ECD is not immunogenic by itself. To break immune self-tolerance, we fused the ECD to the C-terminal of a carrier protein, diphtheria toxin (DTT) ([Figure 1](#fig1){ref-type="fig"}A and 1B).[@bib20], [@bib21] The fusion molecule is designated DPDL1E. The protein was expressed in *E. coli* with a glutathione S-transferase (GST) fusion tag and purified by GST affinity chromatography. After removing the GST tag with PreScission protease (PSP), the molecular weight of the protein was 43.5 kDa ([Figure 1](#fig1){ref-type="fig"}C). The protein was further purified to reduce the level of endotoxin contamination to less than 0.1 endotoxin units (EU)/mL.Figure 1Design of the DPDL1E Vaccine Antigen and Its Recombinant Preparation(A) Schematic representation of the DPDL1E antigen linear structure. (B) Structure model of DPDL1E. (C) SDS-PAGE analysis of DPDL1E antigen expression and purification. Lane 1: induced whole-cell lysate of DPDL1E with the GST tag. Lane 2: induced supernatant of DPDL1E with the GST tag. Lane 3: purified recombinant protein of DPDL1E with the GST tag. Lane 4: product mixture of GST-DPDL1E after PSP digestion. Lane 5: purified DPDL1E.

DPDL1E Immunization Induced PD-L1-Specific Humoral Immune Responses {#sec2.2}
-------------------------------------------------------------------

To examine the immunogenicity of DPDL1E, we first measured the antibody responses by ELISA with the sera of both C57BL/6 and BALB/c mice immunized with either DPDL1E or DTT. Indeed, anti-PD-L1 antibodies were induced in all DPDL1E mice, whereas no PD-L1-specific antibodies were found in DTT-immunized mice ([Figure 2](#fig2){ref-type="fig"}A). Furthermore, we found that the immunoglobulin G (IgG) subclasses were composed of IgG1, IgG2a, IgG2b, and IgG3 ([Figure 2](#fig2){ref-type="fig"}B) and that the level of IgG2 was higher than those of IgG1 and IgG3, indicating that the immune responses were biased toward the Th1 type. The DTT-specific IgG1 was higher than the other antibody subclasses in DPDL1E-immunized mice ([Figure 2](#fig2){ref-type="fig"}B), indicating that anti-DTT immune responses were biased toward the Th2 type. To test the function of anti-PD-L1 antibodies, we performed a binding assay *in vitro* and found that the DPDL1E antisera could efficiently block PD-L1 and PD-1 interaction ([Figure 2](#fig2){ref-type="fig"}C) and that the degree of inhibition was correlated with the antibody titers ([Figure 2](#fig2){ref-type="fig"}D). In a parallel experiment, we used a PD-L1 mAb (10F.9G2) in *in vitro* binding assays. We found that the antibody concentration required to achieve the same level of inhibition was 11.25 μg/mL ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Antibody Responses Induced by DPDL1E Vaccination in C57BL/6 and BALB/c Mice(A) Mice (n = 8) were immunized with DPDL1E three times at 2-week intervals. One week after the third immunization, the antibody titers were measured by ELISA using His-tagged PDL1 recombinant protein as a coating antigen. DTT-immunized serum was used as a negative control. (B) The levels of PD-L1- and DTT-specific antibody subclasses induced by DPDL1E vaccination. Sera were isolated from C57BL/6 and BALB/C mice immunized with the DPDL1E vaccine. The levels of the indicated antibody subclasses were measured by ELISA. (C) The sera from DPDL1E-immunized mice inhibited binding of PD-L1 to PD-1. PD-L1 mAb at 20 μg/mL was used as a positive control, and sera from DTT-immunized mice and PBS were used as a negative control and blank control, respectively. (D) The inhibition efficiency of sera at different concentrations was tested and compared with the control group. (E) A standard curve was created (relative inhibition versus concentration of PD-L1 mAb) to calculate the effective anti-PD-L1 concentration *in vitro*. \*\*\*\*p \< 0.0001.

DPDL1E Vaccine-Induced Cytotoxic T Lymphocyte (CTL) Response {#sec2.3}
------------------------------------------------------------

Because the vaccine induced a Th1-biased type of immunity, we examined the PD-L1-specific CTL response using a lactate dehydrogenase (LDH) release assay. Lymphocytes from DPDL1E-immunized mice were used as effector cells, and PD-L1+ B16-F10 cells were used as target cells. As expected, a significantly high level of cytotoxic activity was observed in DPDL1E-immunized mice compared with DTT-immunized mice (p \< 0.01) ([Figure 3](#fig3){ref-type="fig"}A). Moreover, splenocytes from DPDL1E-immunized mice had a higher stimulation index than those from DTT-immunized mice with His-PD-L1 as a stimulator *in vitro* (p \< 0.05), indicating that PD-L1-specific memory T cells had developed ([Figure 3](#fig3){ref-type="fig"}B). We measured the cytokine levels in the culture supernatants by ELISA. Compared with the DTT control group, the concentrations of interleukin-2 (IL-2), IFN-γ, and tumor necrosis factor alpha (TNF-α) were increased (153.25 pg/mL versus 975.25 pg/mL, 147.5 pg/mL versus 936.25 pg/mL, and 26.32 pg/mL versus 111.25 pg/mL, respectively). We further analyzed PD-L1-induced T cell proliferation *in vitro* by carboxyfluorescein succinimidyl ester (CFSE) profiling ([Figure 3](#fig3){ref-type="fig"}C) and found that PD-L1-specific CD8+ T cells and CD4+ T cells were present in immunized mice splenocytes ([Figure 3](#fig3){ref-type="fig"}D), demonstrating that DPDL1E vaccination can elicit PD-L1-specific cellular immune responses.Figure 3The CTL Response Induced by DPDL1E Vaccination(A) Lymphocytes from spleens of DPDL1E- and DTT-immunized mice were used as effector cells. PD-L1-positive expressed B16-F10 cells were used as target cells. Cytotoxicity was assessed with an LDH release assay. Statistically significant differences were determined using Student's t test. (B) Lymphocytes isolated from DTT- and DPDL1E-immunized mice were stimulated with His-PD-L1 recombinant protein or Con A for 72 h. Cell proliferation was measured with the CCK-8 method. (C) The concentrations of TNF-α, IFN-γ, and IL-2 in supernatant after 72 h stimulation. The cytokines were detected using an ELISA kit. Anti-CD3/CD28 beads (0.5 μg/mL) were used as a positive control. (D) Proliferation of T cells was determined using a CFSE-based assay *in vitro*. CD8+ and CD4+ T cells were gated and analyzed using FCM. Both CD8+ and CD4+ T cells proliferated more than the DTT control group after His-PD-L1 stimulation. Statistically significant differences were calculated by Student's t test. NS, not significant; \*p \< 0.05; \*\*p \< 0.01.

DPDL1E Inhibits Tumor Growth in a Preventive Mouse Model {#sec2.4}
--------------------------------------------------------

To evaluate the efficacy of the vaccine in tumor growth control, we challenged DPDL1E-immunized mice with B16-F10 cells ([Figure 4](#fig4){ref-type="fig"}A) and monitored tumor development in comparison with DTT- or PBS- treated mice. We found that the DPDL1E vaccination significantly inhibited tumor growth, and the median survival was increased from 16 days (PBS group) and 15 days (DTT group) to 23 days (DPDL1E group). Notably, 25% of DPDL1E-vaccinated mice had no tumor growth, and their survival was prolonged beyond 60 days ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [S1](#mmc1){ref-type="supplementary-material"}A). We also noted that the tumor volumes of DPDL1E-immunized mice on day 19 after tumor challenge were correlated with the PD-L1-specific antibodies titers on day 7 after the third immunization (R^2^ = 0.6425) ([Figure 4](#fig4){ref-type="fig"}D), which indicated that anti-PD-L1 antibodies are the major contributors to tumor control. In parallel experiments, we found that the DPDL1E vaccine also inhibits tumor growth in the CT26 colon cancer mouse model ([Figure S2](#mmc1){ref-type="supplementary-material"}).Figure 4Tumor Growth Was Inhibited in DPDL1E-Vaccinated Mice(A) Experimental workflow of the mouse preventive model. Mice were immunized subcutaneously three times at 14-day intervals. On day 7 after the third immunization, mice were injected s.c. with tumor cells. On day 7 after tumor challenge, the fourth immunization was administered. (B) Tumor volume measurements were performed to evaluate tumor growth. The endpoint was predefined by mouse death or a tumor reaching 2 cm in any direction. Statistically significant differences were determined by Mann-Whitney *U* test. (C) A mouse survival curve was constructed after the tumor challenge. Statistically significant differences were determined using a log rank test. (D) A scatterplot with tumor volumes on day 17 as the coordinates of the horizontal axis and serum antibody titers on day 7 after the third immunization as the coordinates of the vertical axis. The correlation coefficient was determined using GraphPad Prism 6 software. (E) The schedule for the metastatic mouse model. (F) Representative images of lung metastasis. (G and H) The total number of nodules (G) and the number of large nodules (H) in the lung. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.

Because B16-F10 is a metastatic cell line, we asked whether DPDL1E vaccination could inhibit metastasis to the lungs. We applied the B16-F10 metastatic model. The mice were sacrificed on day 14 thereafter, and the lungs were checked for tumor nodules ([Figure 4](#fig4){ref-type="fig"}E). An average of 257 and 242 nodules were found in the PBS and DTT groups, respectively, whereas an average of 92 and 79 nodules were found in the DPDL1E group and mAb group, respectively. Furthermore, the number of large nodules (more than 3 mm in diameter) were significantly lower in the DPDL1E group of mice. In a parallel experiments using mAb, we found no significant difference between the DPDL1E group and mAb group in terms of the total number of nodules and the numbers of large nodules ([Figure 4](#fig4){ref-type="fig"}F-G), indicating that DPDL1E vaccination achieved a similar level of protection as mAbs.

DPDL1E Inhibits Tumor Growth in a Therapeutic Mouse Melanoma Model {#sec2.5}
------------------------------------------------------------------

To evaluate the therapeutic efficacy of the DPDL1E vaccine, B16-F10 tumor-bearing C57BL/6 mice were established as described previously.[@bib22], [@bib23] When the tumors were palpable, the mice were treated with DPDL1E or the DTT vaccine. For comparison, another group of mice was treated with a mAb ([Figure 5](#fig5){ref-type="fig"}A). Compared with the isotype or DTT control groups, both the DPDL1E vaccine and PD-L1 mAb inhibited tumor growth ([Figure 5](#fig5){ref-type="fig"}B). The mean survival time of each group was 16.25 days (DTT group), 16.25 days (isotype group), 19 days (DPDL1E group), and 20.25 days (PD-L1 mAb group) ([Figure 5](#fig5){ref-type="fig"}C). More strikingly, tumor growth was markedly inhibited in a subset of mice in both the DPDL1E vaccine- and PD-L1 mAb-treated groups ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 5Therapeutic Efficacy of the DPDL1E Vaccine and Purified Polyclonal Antibody(A) The vaccination (vac) and mAb treatment schedule for the therapeutic mouse melanoma model. (B) Tumor growth curves of different treatment groups after the schedule in (A). C57BL/6 mice (n = 8) were challenged with 2 × 10^5^ B16-F10 cells. On day 4 after the challenge, DPDL1E vaccine was administered s.c. In parallel experiments, PD-L1 mAb were administered i.p. Mann-Whitney *U* test was used to evaluate statistically significant differences. (C) The survival rates of different treatment groups after the schedule in (A). Statistically significant differences were determined using log rank test. (D) The purified polyclonal antibody treatment schedule for the therapeutic mouse melanoma model. (E) Tumor growth curves of different treatment groups after the schedule in (D). C57BL/6 mice (n = 8) were challenged with 2 × 10^5^ B16-F10 cells. On day 4 after the challenge, purified polyclonal antibody from the DPDL1E-immunized group or the control groups were administered i.p. Mann-Whitney *U* test was used to evaluate statistically significant differences. (F) The survival rates of different treatment groups after the schedule in (D). (G and H) Tumor growth curves (G) and survival rates (H) of different treatment groups. Statistically significant differences were determined using log rank test. \*p \< 0.05.

To verify that anti-PD-L1 antibodies were the major contributors, we purified antibodies from the immunized mice and transferred them into unimmunized tumor-bearing mice ([Figure 5](#fig5){ref-type="fig"}D). Compared with antibodies from the control groups, antibodies from DPDL1E immunized mice inhibited tumor growth ([Figure 5](#fig5){ref-type="fig"}E) and prolonged survival ([Figure 5](#fig5){ref-type="fig"}F). These data suggest that PD-L1-specific antibodies play a key role in tumor control.

To test whether a combination of DPDL1E and PD-L1 mAb could benefit therapy, we immunized tumor-bearing mice following the schedule in [Figure 5](#fig5){ref-type="fig"}A. Combination of the DPDL1E vaccine and PD-L1 mAb synergistically inhibited tumor growth ([Figure 5](#fig5){ref-type="fig"}G) and prolonged the survival time ([Figure 5](#fig5){ref-type="fig"}H). These data indicate that the anti-PD-L1 by vaccine approach is promising as an alternative or combinatorial cancer therapy.

DPDL1E Vaccination Increases the Ratio of CD8+ T Cells/Myeloid-Derived Suppressor Cells (MDSCs) in Tumors and Peripheral Blood {#sec2.6}
------------------------------------------------------------------------------------------------------------------------------

Because the level of tumor-infiltrating lymphocytes (TILs) and the ratio of CD8+ T cells/MDSCs have been shown to be associated with anti-tumor immunity,[@bib22], [@bib23] we measured the level of CD8+ T cells in the B16-F10 melanoma model using an immunohistochemistry (IHC) assay. Compared with the DTT-treated group, DPDL1E vaccination increased the level of CD8+ T cell infiltration in both preventive ([Figures 6](#fig6){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A) and therapeutic mouse melanoma models ([Figures 6](#fig6){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). In the therapeutic setting, the levels of CD8+ T cells in DPDL1E-vaccinated mice were 5 times higher than in control mice ([Figure 6](#fig6){ref-type="fig"}B). In a parallel experiment using the anti-PD-L1 mAb, the level of CD8+ T cell infiltration was also significantly increased compared with the isotype control ([Figure 6](#fig6){ref-type="fig"}B). The flow cytometry (FCM) data further confirmed that the DPDL1E vaccine significantly increased T cell infiltration into tumors ([Figure 6](#fig6){ref-type="fig"}C).Figure 6The DPDL1E Vaccine Increased the Levels of TILs and the Ratio of CD8+ T Cells/MDSCs in Tumor Tissues(A and B) Tumor tissues isolated from mice of preventive groups (A) and therapeutic groups (B) were stained with anti-CD8α monoclonal antibody. The IOD was determined by Image-Pro Plus 4.5 software. (C) TILs were further confirmed using FCM. (D)The ratio of CD3+ CD8+ T cells in CD45+ was analyzed using FCM. (E) The ratio of MDSCs in CD45+ was also analyzed using FCM. (F) The ratio of CD8+ T cells/MDSCs was calculated and analyzed. Student's t test was used to determine statistically significant differences. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001.

Next we examined the ratio of CD8+ T cells/MDSCs in tumor tissues and peripheral blood using an FCM assay. The data showed that DPDL1E increased the levels of CD8+ T cells ([Figure 6](#fig6){ref-type="fig"}D) and decreased the levels of MDSCs in tumors ([Figure 6](#fig6){ref-type="fig"}E). The ratio of CD8+ T cells/MDSCs was higher in the DPDL1E and PD-L1 mAb groups than in the isotype or DTT control groups ([Figure 6](#fig6){ref-type="fig"}F). In addition, the DPDL1E vaccine increased the level of CD8+ T cells ([Figure 7](#fig7){ref-type="fig"}A) and decreased the level of MDSCs in peripheral blood ([Figure 7](#fig7){ref-type="fig"}B). Therefore, the ratio of CD8+ T cells/MDSCs in peripheral blood was increased by the vaccine ([Figure 7](#fig7){ref-type="fig"}C). These data suggest that the DPDL1E vaccine reverses the suppressive tumor microenvironment to permit immune-mediated tumor rejection.Figure 7The DPDL1E Vaccine Increased the Ratio of CD8+ T Cells/MDSCs in Peripheral Blood(A and B) The ratio of CD3+ CD8+ T cells (A) and the ratio of MDSCs (B) in CD45+ were analyzed using FCM. (C) The ratio of CD8+ T cells/MDSCs in peripheral blood was calculated and analyzed. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. Student's t test was used to determine statistically significant differences.

The DPDL1E Vaccine Upregulated the Level of PD-L1 and Decreased the Level of LAG3+ PD-1+ T cells in Tumors {#sec2.7}
----------------------------------------------------------------------------------------------------------

Increased expression of PD-1 and LAG3 on TILs is an indicator of impaired T cell function.[@bib24] To examine whether the DPDL1E vaccination has any effect on the expression of PD-1 and LAG3 on TILs, we analyzed their levels in DPDL1E-treated mice as well as in DTT-, isotype-, and PD-L1 mAb-treated mice by FCM. The gating strategies for frequency analyses are shown in [Figure S4](#mmc1){ref-type="supplementary-material"}. The levels of PD-L1+ cells in CD45+ cells from DPDL1E-treated mice were higher than those from DTT- and isotype-treated mice ([Figure 8](#fig8){ref-type="fig"}A), whereas the levels in PD-1+ CD45+ cells from DPDL1E-treated mice were lower than in those from DTT- and isotype-treated mice ([Figure 8](#fig8){ref-type="fig"}B). The levels of LAG3+ as well as PD-1+ LAG3+ CD8+ T cells from DPDL1E- or PD-L1 mAb-treated mice were lower than those from DTT- and isotype--treated mice ([Figures 8](#fig8){ref-type="fig"}C and 8D). There was no significant difference between DPDL1E-treated mice and PD-L1 mAb-treated mice regarding the levels of LAG3+ T cells or PD-1+ LAG3+ T cells. These data suggested that the DPDL1E vaccine decreased inhibitory receptor expression in the tumor microenvironment.Figure 8The DPDL1E Vaccine Decreased the Ratio of PD-1+ Cells and Increased the Ratio of PD-L1+ Cells in Tumors(A) PD-L1+ cells were stained with anti-CD274-APC and anti-CD45-FITC. (B) PD-1+ cells were stained with anti-CD279-APC and anti-CD45-FITC. (C) LAG3+ cells were stained with anti-CD223-PE, anti-CD3-FITC, and anti-CD8-PerCP-Cy5.5. (D) LAG3+PD-1+ cells were stained with anti-CD279-APC, anti-CD223-PE, anti-CD3-FITC, and anti-CD8-PerCP-Cy5.5. All samples were detected using FCM, and the data were analyzed using FlowJo software. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. Statistically significant differences were assessed using Student's t test.

No Adverse Tissue Damage Was Found in DPDL1E-Vaccinated Mice {#sec2.8}
------------------------------------------------------------

To examine the safety of the DPDL1E vaccine *in vivo*, we performed histological analyses of tissues from different treatment groups on day 90 after the third immunization. There was no apparent damage detected by H&E staining ([Figure S5](#mmc1){ref-type="supplementary-material"}A). We further analyzed blood cell counts using an automatic hematology analyzer. The levels of red blood cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B), white blood cells ([Figure S5](#mmc1){ref-type="supplementary-material"}C), or platelets ([Figure S5](#mmc1){ref-type="supplementary-material"}D) were not significantly different between DPDL1E-immunized mice and DTT- or PBS-treated mice. In addition, the mouse body weights were similar among all experimental groups ([Figure S5](#mmc1){ref-type="supplementary-material"}E). These data suggest that DPDL1E vaccination is a safe and tolerable approach for cancer therapy.

Discussion {#sec3}
==========

In this study, we found that immunization of mice with a designed recombinant DPDL1E vaccine delayed tumor growth and increased survival time. The antibodies induced by the DPDL1E vaccine blocked PD-L1 binding to PD-1 *in vitro* and conferred tumor growth control in an adoptive transfer model. Our analyses revealed that the blocking ability of antibodies was significantly associated with antibody titer. We also found that, compared with control groups, the DPDL1E vaccine increased CD8+ T cell infiltration and decreased T cell anergy-associated receptor PD-1 and LAG3 expression in a mouse tumor model.

We determined that the DPDL1E vaccine can induce PD-L1-specific-T cells. Ahmad et al.[@bib25] and Munir et al.[@bib26] have shown that PD-L1-specific CTL enhances antileukemic immunity and can directly lyse PD-L1+ leukemia cells. Thus, a vaccine targeting PD-L1 may have added benefits for cancer therapy. Because therapeutic mAbs restored anti-tumor immunity only in a subset of cancer patients, the PD-L1 vaccine may increase the rate of response by virtue of a PD-L1-specific T cell response. The limitation of this study is that we have not identified PD-L1 T cell epitopes to evaluate a contribution of the T cell response alone in tumor control. However, PD-L1-specific CD8+ T cell and CD4+ T cells were detected *in vitro*.

MDSCs are the major immune suppression cells in both peripheral blood and the tumor environment.[@bib27] MDSCs levels in cancer patients are correlated with clinical stage, and higher MDSCs levels in peripheral blood are associated with a poorer prognosis.[@bib28] We showed that the DPDL1E vaccine confers tumor growth control in part via downregulation of MDSC levels in both peripheral blood and the tumor microenvironment. The levels of PD-1+ and LAG3+ T cells are indicators of T cell dysfunction.[@bib29], [@bib30] The DPDL1E vaccine not only increased T cell infiltration into tumors but also decreased the expression of PD-1 and LAG3 on T cells. These data indicate that the DPDL1E vaccine reverses immune suppression in the tumor microenvironment.

Dendritic cells (DCs) and macrophages play an important role in tumor control and progression.[@bib31], [@bib32] Immune profiling of B16 F10 tumors has identified tumor-infiltrating DCs and macrophages.[@bib33] Antibodies targeting PD-L1 or PD1 enhance DC-mediated T cell activation[@bib34], [@bib35] and shift macrophage polarization toward the M1 type.[@bib36] It warrants further study whether DCs and macrophages in the tumor microenvironment contribute to tumor growth control by the DPDL1E vaccine.

Because many immune cell types express PD-L1,[@bib37] one safety concern regarding the PD-L1 vaccine is be off-target toxic effects. Our results indicate that, in a period of 60 days, these effects are not evident in DPDL1E-immunized mice. A longer term of safety monitoring is warranted for future vaccine development.[@bib38], [@bib39]

According to the data, the major effect of DPDL1E therapy is shown in the preventive model. There are two aspects that should be seriously considered in tumor vaccine evaluation. Compared with mAbs or chemotherapy, the vaccine needs time to trigger the immune response and is more dependent on the status of the immune system. In the present B16-F10 mouse therapy model, tumor progression is so quick that the immune system does not have enough time to control solid tumor growth. The increased volume of tumors does not only weaken the immune response but also promotes the formation of a tumor-suppressive microenvironment. The vaccine strategy would be more effective for residue tumors and early stages of tumors. According to clinical data, people with early cancer have a good prognosis and long survival time.[@bib40], [@bib41] Our results indicate that preexisting PD-L1-specific antibodies can help control tumor growth. The vaccine targeting PD-L1 can been used for these patients after surgery for persistent tumor control. Compared with mAbs, vaccines targeting PD-L1 can reduce the economic burden patients, especially people in less developed countries.

We conclude that the DPDL1E vaccine targeting PD-L1 induced a PD-L1-specific immune response and delayed tumor growth *in vivo*. These results indicate a promising avenue for future research in the quest for cancer vaccine design. The heterogeneity and diversity of tumors indicate that tumor cells have different morphological and phenotypic profiles.[@bib42] The complex nature of cancer is why single therapy has limited efficacy.[@bib43] Thus, combination therapy is necessary to combat advanced stages of cancers. Checkpoint blockade cooperates with a cancer vaccine to enhance antitumor immunity.[@bib23], [@bib44] The combination of PD-L1/PD1 blockade and an oncolytic virus has been discussed in several studies.[@bib45], [@bib46] Blockade of PD-L1/PD1 promotes the efficacy of chimeric antigen receptor T cell (CAR-T) adoptive therapy.[@bib47], [@bib48] The DPDL1E vaccine combined with CAR-T or an oncolytic virus may yield better performance in cancer therapy. Vaccines targeting checkpoints should be considered and combined with other cancer therapy methods.

Materials and Methods {#sec4}
=====================

Cells and Mice {#sec4.1}
--------------

The murine B16-F10 melanoma cell line and the CT26 colon carcinoma cell line were purchased from the ATCC and cultured in DMEM (Thermo Fisher Scientific, San Jose, CA, USA) supplemented with 10% fetal calf serum (FCS), 100 units/mL penicillin, and 100 μg/mL streptomycin (Gibco, Grand Island, NY, USA). Female C57BL/6 and BALB/c mice were purchased from Slac Laboratory Animal (Shanghai, China) and housed in the Shanghai Jiao Tong University Laboratory Animal Center under specific pathogen-free (SPF) conditions. The mouse experiments were carried out following protocols approved by the laboratory animal center of Shanghai Jiao Tong University.

Gene Cloning and Vector Construction {#sec4.2}
------------------------------------

The mouse PD-L1 gene (NM_021893.3) was amplified from total RNA of the C57BL/6 mouse spleen by RT-PCR using the PrimeScript RT Reagent Kit (Takara Bio, Tokyo, Japan), and the gene fragment was inserted into the PMD-18T vector (Takara Bio, Tokyo, Japan). Overlapping PCR was performed to generate the fusion gene DPDL1E consisting of DTT and the PD-L1 ECD (PDL1E). After *EcoR*I and *Xho*I digestion, the fusion gene fragment was inserted into the expression vector pGEX6p-1. All primers are listed in [Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Protein Expression, Purification, and Analysis {#sec4.3}
----------------------------------------------

DPDL1E and DTT were expressed as GST fusion proteins in *E. coli* BL21. The recombinant proteins were purified by GST affinity chromatography as described previously.[@bib21] The GST tag was removed by PSP (GE Healthcare) treatment followed by GST affinity chromatography. Endotoxin was removed using Detoxi-Gel Endotoxin-Removing Columns (Thermo Scientific, USA). Endotoxin levels were monitored using a Limulus amebocyte lysate (LAL) test (GenScript, China). The DPDL1E protein was modeled using the *Ab Initio* Domain Assembly Server (AIDA) and visualized in Discovery Studio Visualizer 3.5.[@bib21], [@bib49]

Immunization and Tumor Challenge {#sec4.4}
--------------------------------

For the tumor-preventive model, 4- to 6-week-old female C57BL/6 or BALB/c mice (n = 8) were immunized subcutaneously three times with the DPDL1E vaccine or DTT protein at 14-day intervals. For each mouse, the vaccine formulation contained 50 μg antigen, 30 μg poly(I:C) (Tocris Bioscience, MO, USA) in 50 μL PBS and 50 μL incomplete Freund's adjuvant (IFA; InvivoGen, San Diego, CA, USA).The DPDL1E vaccine was injected subcutaneously (s.c.) into the right flank or the dorsal part of the mouse. On day 7 after the third immunization, the mouse was injected s.c. with 2 × 10^5^ B16-F10 melanoma cells or 2 × 10^5^ CT26 colon carcinoma cells in the left forelimbs. On day 7 after tumor challenge, the fourth immunization was administered.

To evaluate the effect of DPDL1E on tumor metastasis, we used a lung metastasis model with slight modifications, as reported previously.[@bib50] Briefly, 10^5^ B16-F10 cells were injected intravenously (i.v.) into immunized or non-immunized mice (n = 8), and the mice were sacrificed on day 14 for analysis of lung invasion ([Figure 4](#fig4){ref-type="fig"}E). The total number of tumor nodules and the number of large nodules (\>3 mm) were assessed.

For the tumor therapy model, 4- to 6-week-old female C57BL/6 mice (n = 8) were challenged with a s.c. injection of 2 × 10^5^ B16-F10 melanoma cells in the left forelimbs. When the tumors were palpable (4 days later), mice were immunized s.c. with 50 μg DPDL1E vaccine or 50 μg DTT protein or intraperitoneally (i.p.) administered 200 μg anti-PD-L1 mAb (10F.9G2, Bio X Cell, Japan) or 200 μg control rat IgG (Bio X Cell, Japan) three times at 7-day intervals.[@bib22], [@bib23] DPDL1E (50 μg) and PD-L1 mAb (200 μg) were combined in the therapy model as described above. Tumor diameters were measured every other day with Vernier calipers, and the tumor volumes were calculated using the following formula: volume = (width^2^ × length)/2.[@bib51] The mice had to be sacrificed at a maximal tumor diameter of 2 cm for ethical reasons and were recorded as dead.

Purified Polyclonal Antibody Therapy Model {#sec4.5}
------------------------------------------

The sera isolated from DTT- or DPDL1E-immunized mice were purified using a serum antibody purification kit (Abcam, Cambridge, MA, USA) according to the manufacturer's instruction. When the tumors were palpable (∼4 days later), mice were i.p. administered 400 μg purified antibodies from DPDL1E-immunized mice or 400 μg control purified antibodies from DTT-immunized mice, three times at 3-day intervals. The tumor volumes were measured as described above.

ELISA for Antibody Detection {#sec4.6}
----------------------------

Ninety-six-well plates (Corning Life Sciences, New York, USA) were coated with 100 μL of 1 μg/mL mouse PD-L1 recombinant protein (Sino Biological, Beijing, China) or DTT protein in sodium carbonate buffer (pH 9.6) overnight at 4°C. After washing with PBS and 0.05% Tween 20 (PBST), the plates were blocked with 3% BSA in PBST. The diluted mouse sera were added to wells and incubated for 1 h at 37°C. After washing, 100 μL of 1:5,000 diluted horseradish peroxidase (HRP)-labeled goat anti-mouse subclass antibodies (Thermo Fisher Scientific, San Jose, USA) were added to the wells, and the plates were incubated for 1 h at 37°C. Absorbance was determined at 450 nm using SpectraMax M5 (Molecular Devices, CA, USA).

PD-L1 PD-1 Blockade Assay {#sec4.7}
-------------------------

Serum was isolated from DPDL1E- or DTT-immunized mice 7 days after the third immunization. 96-well plates (Corning Life Sciences, NY, USA) were coated with 100 μL of 5 μg/mL mouse PD-L1 recombinant protein (Acrobiosystems, Bethesda, MD, USA) overnight at 4°C. After washing, 100 μL serum from DPDL1E-immunized mice, 100 μL of 20 μg/mL PD-L1 mAb (10F.9G2, Bio X Cell, Japan), or 100 μL serum of DTT-immunized mice was added to the wells. The plates were incubated at room temperature for 1 h. After washing, 100 μL (2.5 μg/mL) biotin-labeled PD-1 protein (Acrobiosystems, Bethesda, MD, USA) was added to the wells and incubated for 1 h at 37°C. After washing, 100 μL HRP-labeled avidin was added to the wells and incubated for 1 h at 37°C. After washing, 200 μL 3,3',5 ,5'-tetramethylbenzidine (TMB) was added to the wells and incubated for 20 min at room temperature. After incubation, 50 μL 2 M H~2~SO~4~ was added to the wells, and absorbance was determined at 450 nm using SpectraMax M5 (Molecular Devices, Sunnyvale, CA, USA).

Lymphocyte Proliferation Assay {#sec4.8}
------------------------------

C57BL/6 mice (n = 8) were immunized with the DPDL1E or DTT vaccine at 2-week intervals. One week after the third immunization, splenocytes were isolated for further study. Briefly, spleens were isolated from mice under sterile condition and ground into single cells. 5 mL red blood cell (RBC) lysis buffer (Sigma-Aldrich, USA) was added, followed by spinning for 5 min. The cells were filtered through a 70-μM filter (BD Lifesciences, USA) and counted. Splenocytes (1 × 10^6^ /mL in RPMI 1640 medium with 10% FCS) isolated from DPDL1E-immunized mice were cultured in 96-well plate (100 μL/well) and stimulated for 72 h with 50 μg/mL His-PD-L1, 5 μg/mL concanavalin A (Con A; Thermo Fisher Scientific, San Jose, CA, USA), or anti-CD3/CD28 beads (0.5 μg/mL). Splenocytes isolated from DTT-immunized mice were cultured in a 96-well plate and stimulated with 50 μg/mL His-PD-L1 as a negative control. Cell proliferation was measured using a Cell Counting Kit (CCK)-8 kit (Dojindo, Japan). After 72 h stimulation, the supernatant was collected for cytokine detection. The concentrations of TNF-α, IFN-γ, and IL-2 were measured using corresponding ELISA kits (Thermo Fisher Scientific, San Jose, CA, USA).

Splenocytes isolated from DPDL1E- or DTT-immunized mice were stained with CFSE (Dojindo, Japan) according to the manufacturer's instructions and cultured in RPMI 1640 medium containing 10% FCS and 20 units /mL IL-2. The cells were stimulated with His-PD-L1 protein (50 μg/mL) or anti-CD3/CD28 beads (0.5 μg/mL). After 72 h of stimulation, CD8+ and CD4+ T cell proliferation was analyzed by FCM after the cells were stained with anti-CD3-PE, anti-CD8-peridinin chlorophyll protein complex (PerCP)-Cy5.5, and anti-CD4-antigen-presenting cell (APC) (BD Lifesciences, USA).

CTL Assay {#sec4.9}
---------

PD-L1-positive expressed B16-F10 cells were used as target cells, as reported previously.[@bib52] Lymphocytes isolated from DPDL1E-immunized mice were stimulated for 72 h with a His-PD-L1 protein and used as effector cells. Effector cells and target cells were mixed at ratio of 100:1, 50:1, or 20:1 and incubated in Corning Life Sciences 96-well plates at 37°C for 4 h. CTL activities were detected using an LDH cytotoxicity detection kit (Biovision, USA).

FCM Assay {#sec4.10}
---------

A single-cell suspension of peripheral blood from tumor-bearing mice was stained with anti-CD3- fluorescein isothiocyanate (FITC), anti-CD8-PerCP-Cy5.5, anti-CD45-APC or anti-CD45-FITC, anti-CD11b-PerCP-Cy5.5, or anti-Gr1-phycoerythrin (PE). All FCM antibodies were purchased from BD Biosciences. Immune cells in tumor tissue were purified using tumor immune cell separation fluid (Tianjin Hao Yang, China) and stained with anti-CD3-FITC, anti-CD8-PerCP-Cy5.5, anti-CD45-APC or anti-CD45-FITC, anti-CD11b-PerCP-Cy5.5, or anti-Gr1-PE. Cells were also stained with anti-CD45-FITC, anti-CD274-APC (anti-PD-L1) or anti-CD3-FITC, anti-CD8-PerCP-Cy5.5, anti-CD279-APC (anti-PD-1), or anti-CD223-PE (anti-LAG3). Cells were analyzed by FCM (Beckman CytoFLEX, USA). Data were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).

Safety Evaluation {#sec4.11}
-----------------

Different organs isolated from immunized mice were fixed in 4% phosphate-buffered formalin for 24 h and embedded in paraffin. The tissue sections were stained with H&E. The cellular composition of mouse blood was analyzed by an automatic hematology analyzer (Mindray, China). For immunohistochemical detection of CD8+ T cell infiltration, tumor tissue sections were stained with anti-CD8α (rabbit mAb, D4W2Z XP, Cell Signaling Technology, USA). The integral optical density (IOD) of tumor-infiltrating CD8+ T cells was analyzed by Image Pro-Plus software (Media Cybernetics, Silver Spring, MD, USA).

Statistical Analysis {#sec4.12}
--------------------

GraphPad 6 software (San Diego, CA, USA) was used for all data analyses. The difference between two independent datasets was analyzed by Student's t test. The difference in survival time was analyzed by the Kaplan-Meier method and a log rank test. Data are presented as mean ± SD, and p \< 0.05 was considered significant for all tests.
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